Objectives: This study investigated the prognostic significance of three systemic inflammation-based indices—the Lung Immune Prognostic Index (LIPI), the modified Glasgow Prognostic Score (mGPS), and the Pan-Immune-Inflammation Value (PIV)—in patients with extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line platinum-based chemotherapy. Methods: This retrospective study included 135 ES-SCLC patients. LIPI, mGPS, and PIV were calculated from pretreatment laboratory data. Kaplan-Meier and Cox regression analyses were used to evaluate the association of these indices with progression-free survival (PFS) and overall survival (OS). Results: Patients with an LIPI score of 2 experienced significantly worse OS (p=0.002) and PFS (p=0.001) compared to those with a score of 0. No significant association was observed between mGPS or PIV and survival outcomes. Multivariate analysis identified LIPI, prophylactic cranial irradiation, and female sex as independent prognostic factors. A LIPI score two was associated with worse OS (HR: 2.18; p=0.016) and PFS (HR: 2.20; p=0.012), while PCI and female sex were favorable prognostic factors. Conclusion: LIPI is an independent prognostic factor for ES-SCLC patients receiving first-line platinum-based chemotherapy. Incorporating LIPI into clinical practice may improve risk stratification and guide personalized treatment strategies. Keywords: Small cell lung carcinoma; prognostic factors; lung immune prognostic index; modified glasgow prognostic score, pan-immune-inflammation value
Corresponding Author: Irem Oner